Legal News

Gilead’s SPC for HIV treatment invalid as not ‘protected by a basic patent in force’ (Teva v Gilead)

Gilead’s SPC for HIV treatment invalid as not ‘protected by a basic patent in force’ (Teva v Gilead)
Published on: 13 January 2020
Published by: LexisPSL
  • Gilead’s SPC for HIV treatment invalid as not ‘protected by a basic patent in force’ (Teva v Gilead)
  • What are the practical implications of this case?
  • What was the background?
  • What did the court decide?
  • Case details

Article summary

Life sciences analysis: The Court of Appeal has upheld a decision that Gilead’s supplementary protection certificate (SPC) for a product to treat HIV was invalid. The SPC did not comply with Article 3(a) of Regulation (EC) 469/2009 (the SPC Regulation). However the appeal court’s reasoning differed from that of the High Court judge. or take a trial to read the full analysis.

Popular documents